Kennedy said a ‘team' is in Milwaukee to help with lead contamination. The city says that's not true
US Health and Human Services Secretary Robert F. Kennedy Jr. told a Senate subcommittee on Tuesday that the federal government has 'a team in Milwaukee' helping the city address a lead crisis in its schools. The city says that that's not true and that it's still not receiving requested aid from the US Centers for Disease Control and Prevention's childhood lead poisoning experts to deal with the ongoing contamination.
During a Senate Appropriations subcommittee hearing to review the president's HHS budget request for 2026, Kennedy fielded questions about programs and staff already slashed from federal health agencies.
CNN reported in April that the CDC had denied the city's request for help with lead exposures in Milwaukee Public Schools' aging buildings after the agency's lead experts were swept up in widespread cuts at US health agencies. Kennedy and HHS have said that the government plans to continue the work of lead poisoning prevention and surveillance at the new Administration for a Healthy America, rather than the CDC.
The CDC's experts have not been rehired.
'None have been rehired from our lead program or our division,' Dr. Erik Svendsen, who was director of the Division of Environmental Health Science and Practice, which oversaw the childhood lead program, told CNN on Tuesday.
In response to questions Tuesday from Sen. Jack Reed, D-Rhode Island, about the demise of the CDC's childhood lead poisoning prevention program, Kennedy said, 'We are continuing to fund the program, and in Milwaukee, we have a team in Milwaukee, and we're giving laboratory support to that, to the analytics in Milwaukee, and we're working with the health department in Milwaukee.'
Caroline Reinwald, a spokesperson for the City of Milwaukee Health Department, said Kennedy's statement 'is inaccurate.'
'The City of Milwaukee Health Department is not receiving any federal epidemiological or analytical support related to the MPS lead hazard crisis. Our formal Epi Aid request was denied by the CDC,' she wrote in an email from CNN.
Reinwald said the department did recently get help from a lab technician from the CDC's Laboratory Leadership Service, who was there from May 5 to May 16 to help calibrate a new instrument in the city's laboratory.
'This support was requested independently of the MPS crisis and was part of a separate, pre-existing need to expand our lab's long-term capacity for lead testing,' Reinwald said. Beyond the contamination in schools, the city has ongoing programs to test for and remediate lead in its aging homes.
Earlier this month, CNN Chief Medical Correspondent Dr. Sanjay Gupta asked the city's health commissioner, Dr. Michael Totoraitis, if the agency had enough resources to accomplish what it needed to do.
'We have enough of a team right now,' Totoraitis said. 'I think the long-term investigation into the potential chronic exposures of students at the districts is a part that we were really looking to the CDC to help us with, and unfortunately, HHS had laid off that entire team for childhood blood exposure.
'These are the best and brightest minds in these areas around lead poisoning, and now they're gone.'
Andrew Nixon, director of communications for HHS, says the CDC is helping the Milwaukee health agency's lab.
At the health department's request, he said in a statement Tuesday, 'CDC is assisting with validating new lab instrumentation used for environmental lead testing. Staff from [the Milwaukee lab] are focused on the lead response and other routine testing while CDC will assist with testing validation, laboratory quality management, and regulatory requirement documentation to onboard the new laboratory instrument.'
The city says that the CDC lab technician has left and is not expected to return. As of now, it doesn't anticipate any further help from the CDC.
'MHD is proud of the team currently serving Milwaukee families, managing its regular caseload while also responding to the lead crisis in MPS schools. While we would have welcomed federal support, we continue to move forward without it,' Reinwald said in a statement.
At the end of Tuesday's hearing, Wisconsin Sen. Tammy Baldwin, a Democrat, made a statement to 'correct the record.'
'There are no staff on the ground deployed to Milwaukee to address the lead exposure of children in schools, and there are no staff left in that office at CDC, because they have all been fired,' Baldwin told Kennedy. 'I look forward to working with you to reestablish that. It sounds like you have a commitment to that, but we need staff in order to make it function.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
13 minutes ago
- Miami Herald
CDC warns of deadly disease outbreak in key cruise ports
Before you travel, it's always a good idea to review country-specific health information provided by the Centers for Disease Control and Prevention (CDC), as well as travel safety information provided by the U.S. State Department. These notices and travel advisories provide important information to help U.S. citizens guard their health and safety while traveling abroad - whether on a cruise or another type of trip. Related: US changes travel threat level for controversial Caribbean port Although travelers often focus more attention on destination-specific safety and security threats outlined in travel advisories, it's important to consider travel health notices, too. The CDC recently updated some of these notices, including a vital warning for travelers concerning outbreaks of dengue, a common mosquito-borne disease that can have life-threatening health consequences in some cases. More than 13 million cases of dengue were reported across the Americas and in the Caribbean in 2024, and dengue outbreaks in these areas continue in 2025. Sign up for the Come Cruise With Me newsletter to save money on your next (or your first) cruise. The CDC recently updated its travel health notice about global dengue, warning travelers that a number of countries around the world continue to report increased numbers of cases of the serious disease. In its notice, the CDC also explains that health officials are seeing a concerning rise in the number of dengue cases among U.S. travelers returning from certain countries. Dengue outbreaks are reported regularly in many popular tourist destinations, including cruise ports, in the Caribbean, Central America, South America, Southeast Asia, and the Pacific Islands. Related: Royal Caribbean shares new health warning for cruisepassengers Specific countries currently experiencing dengue outbreaks include: BrazilColombiaComorosCubaEcuador, including the Galápagos IslandsFijiFrench Polynesia, including the island groups of Society Islands (Tahiti, Moorea, and Bora-Bora)Marquesas Islands (Hiva Oa and Ua Huka)Austral Islands (Tubuai and Rurutu)GuadeloupeGuatemalaIranMexicoPakistanPanamaPhilippinesSaint LuciaSamoaSudan, and Tonga. Public health officials in Puerto Rico and the U.S. Virgin Islands have also declared dengue outbreaks. If you're taking a cruise to Puerto Rico, the Virgin Islands, Mexico, Panama, or Saint Lucia, you should be especially careful and take steps to protect yourself from dengue. Be the first to see the best deals on cruises, special sailings, and more. Sign up for the Come Cruise With Me newsletter. Dengue is caused by a virus that's spread by mosquito bites, so the CDC advises travelers visiting risk areas to be diligent about preventing them. The CDC's recommendations for mosquito bite prevention include: Use an Environmental Protection Agency (EPA)-registered insect repellentWear long-sleeved shirts and long pants when outdoorsSleep in an air-conditioned room or room with window screens If you do get mosquito bites during a cruise or other trip to a destination with a dengue risk, there are a few things to know and key symptoms to look out for following your trip. Dengue can take up to two weeks to begin, and illness generally lasts less than a week. Symptoms include fever, headache, nausea, vomiting, rash, muscle and joint pain, and minor bleeding. If you develop a fever or experience other symptoms of dengue, you should see a health care provider and inform them of your travel. Related: CDC says throw this food out after salmonella sickens cruisers In some cases, dengue can become severe within a few hours, quickly turning into a medical emergency that typically requires hospitalization. Severe dengue can lead to hemorrhage (uncontrolled bleeding), shock (seriously low blood pressure), organ failure, and even death. Even if you don't get sick, if you've recently visited a dengue risk area, you should also continue protect yourself from mosquito bites upon your return home to reduce the chance of spreading dengue. The CDC advises that travelers returning from a destination with a dengue risk should take steps to prevent mosquito bites for three weeks in order to avoid spreading dengue to mosquitoes that could spread the virus to other people. (The Arena Group will earn a commission if you book a cruise.) Make a free appointment with Come Cruise With Me's Travel Agent Partner, Postcard Travel, or email Amy Post at amypost@ or call or text her at 386-383-2472. Copyright 2025 The Arena Group, Inc. All Rights Reserved
Yahoo
27 minutes ago
- Yahoo
The 3 Most Overlooked and Subtle Signs of Heart Trouble, According to a Cardiovascular Surgeon
The 3 Most Overlooked and Subtle Signs of Heart Trouble, According to a Cardiovascular Surgeon originally appeared on Men's Fitness. Heart disease remains the leading cause of death in the U.S., but recognizing early warning signs could make all the difference. Jeremy London, M.D. is a board certified cardiothoracic surgeon with over 25 years of clinical experience. In a new Instagram post, he shared three of the most common potential heart symptoms you shouldn't ignore. As he says near the end of the video, our bodies have built-in warning systems, and addressing any red flags could save your first and biggest red flag is chest pain. "Or more commonly, chest pressure. It's brought on with activity and relieved with rest, and this is an indication that a portion of the heart muscle may be blood starved," he says. This is referred to as stable angina. The second is more subtle: shortness of breath, particularly associated with activity. "But it's progressive shortness of breath. In other words, it's getting worse over time," he clarifies. The final one is the most subtle of the symptoms, and it's a decrease in exercise tolerance. "Now, we all get tired, but what I'm talking about is fatigue out of proportion to the activity. In other words, like taking out the garbage, taking a shower, crossing the parking lot of the supermarket and having to stop," London says. According to the CDC, heart disease is the leading cause of death for men and women alike. Every 33 seconds, one person dies from cardiovascular disease. In 2022 alone, 702,880 people died from heart disease—the equivalent of one in every five deaths. The key to avoiding becoming part of that statistic is responding to any red flags before you get into 3 Most Overlooked and Subtle Signs of Heart Trouble, According to a Cardiovascular Surgeon first appeared on Men's Fitness on Jun 4, 2025 This story was originally reported by Men's Fitness on Jun 4, 2025, where it first appeared.
Yahoo
34 minutes ago
- Yahoo
California petitions FDA to undo RFK Jr.'s new limits on abortion pill mifepristone
California and three other states petitioned the U.S. Food and Drug Administration Thursday to ease its new restrictions on the abortion pill mifepristone, citing the drug's proven safety record and arguing the new limits are unnecessary. "The medication is a lifeline for millions of women who need access to time-sensitive, critical healthcare — especially low-income women and those who live in rural and underserved areas," said California Atty. Gen. Rob Bonta, who filed the petition alongside the attorneys general of Massachusetts, New York and New Jersey. The petition cites Senate testimony by Health and Human Services Secretary Robert F. Kennedy Jr. last month, in which Kennedy said he had ordered FDA administrator Martin Makary to conduct a "complete review" of mifepristone and its labeling requirements. The drug, which can be received by mail, has been on the U.S. market for 25 years and taken safely by millions of Americans, according to experts. It is the most common method of terminating a pregnancy in the U.S., with its use surging after the Supreme Court overturned Roe vs. Wade in 2022. The Supreme Court upheld access to the drug for early pregnancies under previous FDA regulations last year, but it has remained a target of anti-abortion conservatives. The Trump administration has given Kennedy broad rein to shake up American medicine under his "Make America Healthy Again" banner, and Kennedy has swiftly rankled medical experts by using dubious science — and even fake citations — to question vaccine regimens and research and other longstanding public health measures. Read more: Hiltzik: MAHA report's misrepresentations will harm public health and hit consumers' pocketbooks At the Senate hearing, Kennedy cited "new data" from a flawed report pushed by anti-abortion groups — and not published in any peer-reviewed journal — to question the safety of mifepristone, calling the report "alarming." "Clearly, it indicates that, at very least, the label should be changed," Kennedy said. Sen. Josh Hawley (R-Mo.) on Monday posted a letter from Makary to X, in which Makary wrote that he was "committed to conducting a review of mifepristone" alongside "the professional career scientists" at the FDA. Makary said he could not provide additional information given ongoing litigation around the drug. The states, in their 54-page petition, wrote that "no new scientific data has emerged since the FDA's last regulatory actions that would alter the conclusion that mifepristone remains exceptionally safe and effective," and that studies "that have frequently been cited to undermine mifepristone's extensive safety record have been widely criticized, retracted, or both." Democrats have derided Kennedy's efforts to reclassify mifepristone as politically motivated and baseless. "This is yet another attack on women's reproductive freedom and scientifically-reviewed health care," Gov. Gavin Newsom said the day after Kennedy's Senate testimony. "California will continue to protect every person's right to make their own medical decisions and help ensure that Mifepristone is available to those who need it." Bonta said Thursday that mifepristone's placement under the FDA's Risk Evaluation and Mitigation Strategy program for drugs with known, serious side effects — or REMS — was "medically unjustified," unduly burdened patient access and placed "undue strain on the nation's entire health system." He said mifepristone "allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive," is "so safe that it presents lower risks of serious complications than taking Tylenol," and that its long safety record "is backed by science and cannot be erased at the whim of the Trump Administration." Read more: Q&A: The FDA says the abortion pill mifepristone is safe. Here's the evidence The FDA has previously said that fewer than 0.5% of women who take the drug experience 'serious adverse reactions,' and deaths are exceedingly rare. The REMS program requires prescribers to add their names to national and local abortion provider lists, which can be a deterrent for doctors given safety threats, and pharmacies to comply with complex tracking, shipping and reporting requirements, which can be a deterrent to carrying the drug, Bonta said. It also requires patients to sign forms in which they attest to wanting to "end [their] pregnancy," which Bonta said can be a deterrent for women using the drug after a miscarriage — one of its common uses — or for those in states pursuing criminal penalties for women seeking certain abortion care. Under federal law, REMS requirements must address a specific risk posed by a drug and cannot be "unduly burdensome" on patients, and the new application to mifepristone "fails to meet that standard," Bonta said. The states' petition is not a lawsuit, but a regulatory request for the FDA to reverse course, the states said. If the FDA will not do so nationwide, the four petitioning states asked that it "exercise its discretion to not enforce the requirements" in their states, which Bonta's office said already have "robust state laws that ensure safe prescribing, rigorous informed consent, and professional accountability." Get the L.A. Times Politics newsletter. Deeply reported insights into legislation, politics and policy from Sacramento, Washington and beyond, in your inbox twice per week. This story originally appeared in Los Angeles Times.
